Characterization of anticancer therapy–induced microvascular dysfunction in patients with breast cancer supports targeted intervention
Authors:
- Janée D. TerwoordJTJanée D. Terwoord
- Shelby N. HaderSHShelby N. Hader
- Stephen T. HammondSHStephen T. Hammond
- Joseph C. HockenberryJHJoseph C. Hockenberry
- Jasmine LinnJLJasmine Linn
- Ibrahim Y. VazirabadIVIbrahim Y. Vazirabad
- Amanda L. KongAKAmanda L. Kong
- Alison J. KriegelAKAlison J. Kriegel
- Ziqing LiuZLZiqing Liu
- Riikka M. KiveläRKRiikka M. Kivelä
- Gillian MurtaghGMGillian Murtagh
Open Access
- 30 September 2025
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (22)
Abstract
BACKGROUND: Cardiotoxicity is a major complication of anticancer therapy (CTx); however, the effect of CTx on the microcirculation is not well defined. This study evaluated the effect of CTx on microvascular function in patients with breast cancer (PwBC). METHODS: Endothelial function and angiogenic potential were assessed in arterioles and adipose biopsies obtained from PwBC undergoing CTx (longitudinal and cross-sectional) and in healthy arterioles exposed to doxorubicin (Dox), trastuzumab (TZM), or paclitaxel (PTX) ex vivo. VEGF-B protein was used to test feasibility of targeted intervention. RESULTS: PwBC treated with Dox and/or TZM developed profound microvascular endothelial dysfunction that persisted for ≥ 9 months after treatment cessation. Angiogenic potential was reduced during CTx and recovered within 1 month. Gene expression related to angiogenesis and inflammation changed over the course of clinical treatment. Adipose arterioles from healthy donors developed endothelial dysfunction when exposed to Dox or TZM ex vivo. PTX, which poses minimal cardiovascular risk, had no effect on vasomotor function. Ex vivo exposure to Dox or PTX suppressed angiogenic potential, whereas TZM had no effect. VEGF-B protein preserved endothelial function in arterioles exposed to Dox or TZM ex vivo. CONCLUSION: PwBC undergoing treatment with Dox and/or TZM develop prolonged microvascular endothelial dysfunction that is recapitulated in healthy arterioles exposed to Dox or TZM ex vivo. Targeted intervention with VEGF-B protects against direct Dox- or TZM-induced vascular toxicity in human arterioles ex vivo. FUNDING: NIH, American Heart Association, WeCare Foundation, Medical College of Wisconsin, Advancing a Healthier Wisconsin, Jenny and Antti Wihuri Foundation.Keywords
Funding Information
- National Institutes of Health (HL133029)
- National Institutes of Health (HL134643)
- American Heart Association (SFRN847970)
- We Care Foundation (N/A)
- Medical College of Wisconsin (Cardiovascular Center Pre-PPG Grant)
- Advancing a Healthier Wisconsin Endowment (Redox Biology Grant)
- Jenny ja Antti Wihurin Rahasto (N/A)
- National Heart, Lung, and Blood Institute (HL173549)
This publication has 77 references indexed in Scilit:
- Cardio-oncology: Shared Genetic, Metabolic, and Pharmacologic MechanismCurrent Cardiology Reports, 2023
- Coronary vasomotor dysfunction portends worse outcomes in patients with breast cancerJournal of Nuclear Cardiology, 2022
- Cardiac complications of cancer therapies2022
- Protective effect of HINT2 on mitochondrial function via repressing MCU complex activation attenuates cardiac microvascular ischemia–reperfusion injuryBasic Research in Cardiology, 2021
- Causes of death after breast cancer diagnosis: A US population‐based analysisCancer, 2019
- Effects of high-intensity interval training on vascular endothelial function and vascular wall thickness in breast cancer patients receiving anthracycline-based chemotherapy: a randomized pilot studyBreast Cancer Research and Treatment, 2019
- Transition in the mechanism of flow-mediated dilation with aging and development of coronary artery diseaseBasic Research in Cardiology, 2016
- VEGF‐B‐induced vascular growth leads to metabolic reprogramming and ischemia resistance in the heartEMBO Molecular Medicine, 2014
- Adipose Tissue Angiogenesis Assay2014
- A comparative study on the anti-angiogenic effects of DNA-damaging and cytoskeletal-disrupting agentsAngiogenesis, 2009